Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Lubel J, Strasser S, Stuart KA, Dore G, Thompson A, Pianko S, Bollipo S, Mitchell JL, Fragomeli V, Jones T, Chivers S, Gow P, Iser D, Levy M, Tse E, Gazzola A, Cheng W, Nazareth S, Galhenage S, Wade A, Weltman M, Wigg A, MacQuillan G, Sasadeusz J, George J, Zekry A, Roberts SK; Australian Liver Association Clinical Research Network (ALA CRN).
Lubel J, et al. Among authors: pianko s.
Antivir Ther. 2017;22(8):699-710. doi: 10.3851/IMP3168.
Antivir Ther. 2017.
PMID: 28422043